Compare RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) (RELX) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) vs BIO-TECHNE Corp — how do they compare? RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) trades at $36.73 (market cap $63.57B), while BIO-TECHNE Corp trades at $72.69 (market cap $11.37B). The key difference: RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) is far larger — about 5.6× BIO-TECHNE Corp's market cap, and RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| RELX | TECH | |
|---|---|---|
Market Cap | $63.57B | $11.37B |
Volume | 1,602,093 | 2,420,565 |
Sector | Industrials | Health |
52-Week High | $46.80 | $72.61 |
52-Week Low | $27.73 | $43.31 |
Enterprise Value | $75.05B | $11.39B |
Dividend Yield | 2.49% | 0.44% |
Typical Hold Time | — | 64 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RELX trades at $36.70, up 0.44% with neutral technical signals. The company demonstrates strong profitability with 23.27% net margins and 132.36% ROE, though valuation metrics appear elevated with P/E of 22.21 and P/B of 38.89. Recent earnings show mixed results with Q2 2026 beating expectations while Q4 2025 missed. Analyst sentiment remains positive with 71% buy ratings and consensus price target of $26.00.
The investment case balances strong fundamentals against premium valuation. Growth catalysts include AI-driven product adoption and margin expansion, while risks involve competitive pressures and valuation concerns. With solid cash flow generation and institutional support, RELX offers quality exposure but requires monitoring of valuation multiples and competitive dynamics.
Bio-Techne (TECH) trades at $72.50, near its 52-week high of $72.70, with a slight daily decline of 0.08%. Technical indicators show a bullish trend, while valuation ratios like a P/E of 62.5 suggest premium pricing. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share is a key development. Earnings have been mixed, with a beat in Q2 2026 but a miss in Q1 2026, and net income declined to $73.40 million in 2025 from $168 million in 2024.
The stock's outlook is supported by the pending acquisition, offering a near-term upside to the $73.00 buyout price. However, high valuation and earnings volatility pose risks. Analyst sentiment is balanced with 46% buy ratings, but no sell recommendations. Investors should weigh the acquisition premium against fundamental concerns like margin compression.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share)
RELX PLC is a UK-based information and analytics company operating across four segments: Risk (fraud prevention and compliance analytics via LexisNexis Risk Solutions), Scientific, Technical & Medical (Elsevier's research and clinical content), Legal (LexisNexis Legal & Professional's research tools), and Exhibitions (RX's trade events). It serves professional, business, and government customers worldwide.
Read more on RELX →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
